FEATURES OF CARBOHYDRATE AND LIPID METABOLISM IN PREGNANT WOMEN WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnancy often has a latent course, complicating diagnosis. To evaluate the dynamics of carbohydrate and lipid metabolism parameters in pregnant women with MASLD in the II-III trimesters and compare it with the dynamics of non-invasive indicators of liver steatosis and stiffness. Materials and Methods. 70 pregnant women with cardiometabolic risk factors were examined. Carbohydrate and lipid profiles, along with ALT/AST levels, were assessed. Ultrasound steatometry and two-dimensional shear wave elastography were performed. Results. In the second trimester, patients exhibited clear signs of insulin resistance, dyslipidemia, and initial steatosis (S1) in the complete absence of fibrosis (F0). Pronounced metabolic disturbances were recorded in the third trimester: a statistically significant (p<0.05) increase in the HOMA index by more than twofold. Increasing insulin resistance was associated with a worsened lipid profile and the development of atherogenic dyslipidemia, resulting in significantly increased levels of triglycerides, non-HDL cholesterol, and the atherogenic index (p<0.05). Escalating lipotoxic stress directly led to the progression of structural liver changes: parenchymal stiffness significantly (p<0.05) increased, reaching values that correspond to the latent early fibrosis range (stage F1 by the METAVIR scale). At the same time, manifest cytolytic syndrome was absent: mean ALT and AST values in the second trimester were within normal limits, and in the third trimester they showed an upward trend, only slightly exceeding the upper reference limit, which confirms the subclinical (latent) nature of liver damage. Conclusions. In pregnant women with MASLD, carbohydrate metabolism disorders deepen during the II-III trimesters (a significant increase in HOMA-IR), and the lipid profile changes (an increase in triglycerides, non-HDL cholesterol, LDL, and the atherogenic index). Mild liver steatosis persists without significant dynamics, whereas parenchymal stiffness significantly increases to the F1 range. Since these changes occur without a pronounced cytolytic syndrome, the isolated determination of ALT and AST is insufficient. A combined assessment of metabolic indicators and ultrasound parameters is a promising approach for the dynamic monitoring of such pregnant women.